Business Context and Reporting Period
This Form 8-K Current Report was filed by Aileron Therapeutics, Inc. (not Rein Therapeutics, Inc.) on March 15, 2024, covering events occurring on March 11, 2024. The filing details significant executive leadership transitions within the biopharmaceutical company.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, there are no reported values for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
- CEO Departure: Manuel C. Alves-Aivado, M.D., Ph.D., resigned as Chief Executive Officer effective March 11, 2024. He will remain on the Board of Directors as a non-employee director.
- CEO Appointment: Brian Windsor, Ph.D., was elected Chief Executive Officer and a member of the Board of Directors effective March 11, 2024. Dr. Windsor continues to serve as President.
- Severance Terms: Dr. Alves-Aivado is entitled to 18 months of base salary, COBRA medical premiums for up to 18 months, a lump sum equal to 1.5 times his 2024 target bonus, and full acceleration of unvested equity awards, contingent upon signing a release of claims.
Guidance, Outlook, and Risks
The filing states that Dr. Alves-Aivado's resignation was not the result of any disagreement with the Company regarding operations, policies, or practices. No financial guidance, outlook, or specific risk factors were disclosed in this report. A press release regarding these transitions was issued on March 12, 2024, and is included as an exhibit.
Investor Verification Checklist
- Verify the exact terms of the Severance Agreement dated September 6, 2018, to confirm the total potential payout to the departing CEO.
- Review the press release (Exhibit 99.1) for additional strategic context regarding the leadership change.
- Confirm Dr. Windsor's prior compensation and any new equity grants associated with his promotion to CEO.
- Check subsequent filings for any impact on the company's operational pipeline or strategic direction following the transition.